06/11/2025
Medical Advisory: Managing Morbid Obesity with GLP-1 Receptor Agonists
(For Diabetic and Non-Diabetic Patients)
Morbid obesity is a complex, chronic medical condition that significantly increases the risk of diabetes, cardiovascular disease, fatty liver, and other metabolic disorders. When lifestyle modification alone is insufficient, GLP-1 receptor agonists have emerged as an evidence-based therapeutic option.
About GLP-1 Therapy (Semaglutide / Liraglutide)
GLP-1 receptor agonists mimic the body’s natural incretin hormone, helping regulate appetite, glucose metabolism, and body weight.
Clinical studies have demonstrated:
Sustained weight reduction in both diabetic and non-diabetic individuals
Improved glycaemic control and insulin sensitivity
Decreased appetite and food cravings
Reduced cardiovascular risk factors
Who May Benefit:
Patients with BMI ≥ 30 (Obesity)
Individuals with Type 2 Diabetes and weight gain
Those who have not achieved desired results with diet and exercise alone
Important:
GLP-1 therapy must be prescribed and monitored by a qualified physician to ensure safety, correct dosage titration, and management of potential side effects.
📍 Doctors Clinic
Comprehensive Care in Diabetes, Obesity & Internal Medicine
🌐 www.doctorsclinic.com.pk
📧 info@doctorsclinic.com.pk
📞 0333-1742497